A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

ClinicalTrials.gov ID: NCT03517488

Public ClinicalTrials.gov record NCT03517488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Study identification

NCT ID: NCT03517488
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Xencor, Inc.; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Interventions

XmAb20717 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 9, 2018
Primary completion: May 31, 2022
Completion: Sep 5, 2022
Last update posted: Nov 30, 2022

2018 – 2022

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute	Los Angeles	California	90048	—
UCLA Hematology-Oncology Clinic (Westwood)	Los Angeles	California	90095	—
University of California San Diego Moores Cancer Center	San Diego	California	92093-0698	—
University of California San Francisco Medical Center	San Francisco	California	94115	—
Emory University	Atlanta	Georgia	30322	—
University of Chicago Medicine	Chicago	Illinois	60637	—
The University of Kansas Clinical Research Center	Fairway	Kansas	66205	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	10016	—
Columbia University Medical Center - Herbert Irving Pavilion	New York	New York	10032	—
Providence Portland Medical Center	Portland	Oregon	97213	—
Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	—
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah	84112	—
Emily Couric Clinical Cancer Center	Charlottesville	Virginia	22903	—
Seattle Cancer Care Alliance	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03517488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 30, 2022 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03517488 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →